Clinical trial · Observational
Glofitamab in Real Life
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To date, more than 300 patients have been treated with Glofitamab in the Expanded Access Programme (EAP) in France. In this study, it is proposed to perform a retrospective analysis of some of these patients. The aim is to describe the efficacy and safety of Glofitamab in the largest reported real-world cohort, with an expected median follow-up of more than 9 months. Particular focus will be given to the relapsed or refractory chimeric antigen receptors-T (CAR-T) population to confirm the response rates (CRR: 35-39%) of Glofitamab in this population and to assess the optimal timing of therapy initiation \[8, 15\].
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Large B-cell Lymphoma | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Glofitamab | Drug | Glofitamab | ALIAS |
Design
Arms and outcomes
Arms (1)
- label
- Patients treated in EPA
- description
- Patients treated in Expanded Access Program to Glofitamab
- interventionNames
- Drug: Glofitamab
Primary outcomes (1)
- measure
- Best Complete Response Rate (best CRR) during treatment, assessed by investigator according to Lugano 2014 criteria.
- timeFrame
- 6 months
Secondary outcomes (9)
- measure
- Complete metabolic response rate and overall response rate (ORR) by investigator assessment according to Lugano 2014 criteria
- timeFrame
- 1 month, 2 months, 3 months, 6 months
- measure
- Progression-free survival (PFS)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * patient enrolled in the French Glofitamab EAP for R/R DLBCL before 2024 November 1st, 2024 * patient who received at least Obinutuzumab pretreatment and one infusion of Glofitamab * adult patient * patient who is informed of the study and who did not oppose to their data collection Exclusion Criteria: * none
References
Publications (0)
Data not yet available